Immunomodulatory Properties of Stem Cells from Human Exfoliated Deciduous Teeth
Overview
Authors
Affiliations
Introduction: Stem cells from human exfoliated deciduous teeth (SHED) have been identified as a population of postnatal stem cells capable of differentiating into osteogenic and odontogenic cells, adipogenic cells, and neural cells. Herein we have characterized mesenchymal stem cell properties of SHED in comparison to human bone marrow mesenchymal stem cells (BMMSCs).
Methods: We used in vitro stem cell analysis approaches, including flow cytometry, inductive differentiation, telomerase activity, and Western blot analysis to assess multipotent differentiation of SHED and in vivo implantation to assess tissue regeneration of SHED. In addition, we utilized systemic SHED transplantation to treat systemic lupus erythematosus (SLE)-like MRL/lpr mice.
Results: We found that SHED are capable of differentiating into osteogenic and adipogenic cells, expressing mesenchymal surface molecules (STRO-1, CD146, SSEA4, CD73, CD105, and CD166), and activating multiple signaling pathways, including TGFbeta, ERK, Akt, Wnt, and PDGF. Recently, BMMSCs were shown to possess an immunomodulatory function that leads to successful therapies for immune diseases. We examined the immunomodulatory properties of SHED in comparison to BMMSCs and found that SHED had significant effects on inhibiting T helper 17 (Th17) cells in vitro. Moreover, we found that SHED transplantation is capable of effectively reversing SLE-associated disorders in MRL/lpr mice. At the cellular level, SHED transplantation elevated the ratio of regulatory T cells (Tregs) via Th17 cells.
Conclusions: These data suggest that SHED are an accessible and feasible mesenchymal stem cell source for treating immune disorders like SLE.
Kiyokawa Y, Terajima M, Sato M, Inada E, Hori Y, Bando R J Clin Med. 2024; 13(23).
PMID: 39685514 PMC: 11642068. DOI: 10.3390/jcm13237058.
Osteogenic potency of dental stem cell-composite scaffolds in an animal cleft palate model.
Rattanapinyopituk K, Chaweewannakorn C, Tangjit N, Dechkunakorn S, Anuwongnukroh N, Sritanaudomchai H Heliyon. 2024; 10(16):e36036.
PMID: 39224373 PMC: 11367540. DOI: 10.1016/j.heliyon.2024.e36036.
Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options.
Mello D, Mesquita F, Silva Dos Santos D, Asensi K, Dias M, Campos de Carvalho A Int J Mol Sci. 2024; 25(11).
PMID: 38892249 PMC: 11173248. DOI: 10.3390/ijms25116063.
Mao Z, Wang C, Liu J, Li X, Duan H, Ye Y Gene Ther. 2024; 31(7-8):422-433.
PMID: 38834681 DOI: 10.1038/s41434-024-00457-x.
Jenkner S, Clark J, Gronthos S, OHare Doig R Cells. 2024; 13(10.
PMID: 38786039 PMC: 11119219. DOI: 10.3390/cells13100817.